Executives
-
O'Sullivan MiriamSVP, Chief HR Officer -
Sorenson John BradleyEVP, Global Operations
-
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
-
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
-
Brown Vance RSVP, GC and Corp. Secretary
-
Brennan Daniel J.EVP and CFO
-
Carruthers WendyEVP, Human Resources
-
Woodworth EmilySVP, Global Controller and CAO
-
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
-
Monson JonathanSVP, Global Controller and CAO
?
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
Boston Scientific Corporation
US, Marlborough [HQ]
CIK
1566094
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
726,040,000
Price per Share :
$98.66
Equivalence :
$71,631,106,400.00
Transaction History
-
S726,040,000 Shares After TransactionValue : $48,172,754,000.00Sold $3,290,960,000.00Transaction Date : 02/21/24
-
Footnotes
-
-
Footnotes:#1 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023.
-
A832,540,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
-
F710,940,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
-
M755,740,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/16/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.#2 Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.
-
F742,190,000 Shares After TransactionValue : $48,850,945,800.00$891,861,000.00Transaction Date : 02/16/24
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.#2 Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.